Codes ATC:
J01CR02
EMLc
Indication
Multi-drug resistant Mycobacterium tuberculosis
Code ICD11:
ML32.00
INN
Amoxicillin + clavulanic acid
Type de médicament
Chemical agent
Groupes d'antibiotiques
Type de liste
Liste de base
(EML)
(EMLc)
(EMLc)
Additional notes
For use only in combination with meropenem or imipenem + cilastatin (EML). For use only in combination with meropenem (EMLc)
Formulations
Oral > Liquid:
250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
(EMLc)
Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc)
Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc)
Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Historique des statuts LME
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Wikipédia
DrugBank
Résumé des preuves et recommandation du comité d'experts
The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of amoxicillin + clavulanic acid 250 mg + 62.5 mg dispersible tablets to the EMLc.